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A vascularized tumoroid 
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Glioblastoma (GBM) angiogenesis is critical for tumor growth and recurrence, making it a compelling 
therapeutic target. Here, a disease-relevant, vascularized tumoroid in vitro model with stem-
like features and stromal surrounds is reported. The model is used to recapitulate how individual 
components of the GBM’s complex brain microenvironment such as hypoxia, vasculature-related 
stromal cells and growth factors support GBM angiogenesis. It is scalable, tractable, cost-effective 
and can be used with biologically-derived or biomimetic matrices. Patient-derived primary GBM cells 
are found to closely participate in blood vessel formation in contrast to a GBM cell line containing 
differentiated cells. Exogenous growth factors amplify this effect under normoxia but not at hypoxia 
suggesting that a significant amount of growth factors is already being produced under hypoxic 
conditions. Under hypoxia, primary GBM cells strongly co-localize with umbilical vein endothelial 
cells to form sprouting vascular networks, which has been reported to occur in vivo. These findings 
demonstrate that our 3D tumoroid in vitro model exhibits biomimetic attributes that may permit its 
use as a preclinical model in studying microenvironment cues of tumor angiogenesis.
Glioblastoma (GBM) is the most common and aggressive form of brain  cancer1, characterized by significant cell 
 heterogeneity2, self-renewing cancer stem  cells3, and rich  microvasculature4. Tumor progression is intimately 
linked with changes to the tumor microenvironment, including modulation of the extracellular matrix (ECM) 
and basement membrane  compositions5,6, disruption of the blood brain  barrier7, changes to matrix moduli and 
 density8,9, and inducing a wide range of interactions between endothelial and stromal cell  populations4,10. One of 
most significant features of GBM is its hypervascularity and there is a significant correlation between the degree 
of angiogenesis and  prognosis11,12. A significant challenge exists to accurately recreate this neoangiogenesis and 
the tumor microenvironment through personalised in vitro disease models, which would support the develop-
ment of new anti-angiogenic treatments to GBM.
Hypoxic and necrotic conditions characterize the GBM tumor  microenvironment13 and lead to complex 
mechanisms supporting the formation of new vessels and recruitment of immunosuppressive  cells14. Through 
HIF-1 signalling, these hypoxic and necrotic niches activate and enrich glioblastoma stem cells (GSCs), induce 
the transdifferentation of GSCs into endothelial cells, and upregulate the release of pro-angiogenic growth fac-
tors, such as vascular endothelial growth factors (VEGF) and basic fibroblast growth factor (bFGF)4. Notably, 
tumors that have a high stem cell number are highly  angiogenic15,16.
Alongside xenograft and genetically engineered transplant  models17,18, there is a significant need for 3D 
in vitro models which can be studied under highly controllable conditions (e.g. modulating matrix properties, cell 
population and signalling factor compositions), for basic research and for rapid drug testing. Furthermore, 3D 
cell culture models outperform 2D models at replicating the in vivo tumor  processes19,20. To this end, 3D aggre-
gates of tumor cells (i.e. tumoroids) can be generated in vitro which exhibit key biomimetic properties including 
hypoxic responses, interactions with the ECM microenvironment, heterogeneous stroma cells, molecular signal 
gradients and differential nutrient and waste  transport21. While several 3D human GBM models have been 
investigated, most notably looking at the ECM composition, organization, and drug resistance and  penetration21, 
there is a need for the development of tumoroid models which mimic the dynamics of tumor angiogenesis, given 
the importance vascularization plays in glioblastoma progression.
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Here, we introduce a 3D vascularized tumoroid in vitro model using patient-derived primary GBM cells. 
This model is used to recapitulate how individual components of the GBM’s complex brain microenvironment, 
such as low oxygen tension (e.g. 1%  O2), vasculature-related stromal cells (e.g. human umbilical vein endothe-
lial cells (HUVEC), human dermal fibroblasts (HDF) and growth factors (e.g. VEGF, bFGF), support the GBM 
angiogenesis.
Results and discussion
The vascularized tumoroid model is based on spheroids, in which HUVEC and patient-derived primary GBM 
are in direct contact with each other, supported by HDF embedded in a fibrin gel (Fig. 1A). The NCH82 GBM 
cell line is also used. Variants of the model include GBM-only or HUVEC-only spheroids surrounded by HDF, 
GBM or no cells in the fibrin gel. It should be noted that direct comparison between the two cell lines is not 
possible because different types of culture medium were used.
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Figure 1.  (A) Schematic representation of the formation of a vascularized tumoroid model from patient-
derived primary glioblastoma cells. (B) Fluorescence images showing angiogenic sprouting at 1% and 20%  O2 
at day 3 after seeding of (i) HUVEC (red) spheroid, supported by single HDF cells with or without additional 
growth factors; (ii) NCH82 (green) or primary (green) GBM spheroids and (iii) the full vascularized tumoroid 
model containing NCH82 or primary GBM : HUVEC spheroids with HDF supporting cells. HDF cells are non-
fluorescent. The spheroids and single HDF cells are embedded in a 7.5 mg/mL fibrin gel. The scale bars represent 
250 µ m. (C) Graphical representations of (i) the total vessel area and vessel length for HUVEC spheroids 
surrounded by HDF, with or without additional growth factors and (ii) the total spheroid area for NCH82 or 
primary GBM spheroids. Data are presented as the mean ± standard deviation; n = 3; *p < 0.05, **p < 0.01, ***p 
< 0.001. Subscript S denotes cells seeded in the same spheroid.
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Sprouting of HUVEC spheroids. The first challenge towards the development of the vascularized tumor-
oid model is to provide a suitable environment for the HUVEC spheroids to form capillary sprouts. Angiogenesis 
is a complex process involving dynamic interactions between the endothelial and stromal cells, the production 
of angiogenic signalling factors, and is affected by changes in the surrounding ECM (e.g. hypoxic conditions). 
Fibrin was chosen as the supporting matrix for our experiments because it can be derived directly from the 
patients’  blood22. Variation in the ECM composition is a hallmark of tumor stroma, with increased fibrin deposi-
tion associated with tumor  angiogenesis23. Pro-angiogenic factors, such as VEGF and bFGF, have a high affinity 
for fibrin through the heparin binding  domain24. Fibrin also triggers the production of other basement mem-
brane proteins that are strongly linked to angiogenesis such as laminin and collagen  IV25.
In the absence of a supporting cell type, endothelial cells cultured in spheroids within a fibrin gel undergo a 
migratory response instead of forming vasculature (Figure S1). In angiogenesis models, a range of supporting 
cells can be used including human dermal fibroblasts, mesenchymal stromal cells and pericytes. In this study, 
we used the well-known method of culturing endothelial cells with human dermal fibroblasts, as they undertake 
significant collagen deposition and produce pro-angiogenic growth factors enabling capillary  formation26. To 
this end, HUVEC spheroids are cultured with HDF single cells (at 106 cells/mL) within a 7.5 mg/mL fibrin gel 
to form angiogenic sprouts. Experiments are performed under normoxia (20%  O2) or hypoxia (1%  O2), with or 
without additional pro-angiogenic growth factors (200 ng/mL VEGF and bFGF). Figure 1B(i) shows a typical 
HUVEC spheroid at day 3 after seeding (additional timepoints are shown in Figure S2). In all cases the HUVEC 
display an angiogenic-like response, sprouting radially outwards forming capillaries. The addition of exogenous 
growth factors, as well as normoxia, induce a stronger angiogenic response compared to hypoxia. Figure 1C(i) 
shows the increase in vessel area and total vessel length of the produced sprouts at day 3.
Invasion of GBM spheroids. Before incorporating the tumor cells into the sprouting spheroids, the inva-
sion capability of GBM-only spheroids embedded in a fibrin gel was examined for primary and NCH82 GBM 
cells under hypoxic and normoxic conditions. Figure 1B(ii) shows fluorescence images of the GBM spheroids at 
day 3. The corresponding total spheroid areas are shown in Fig. 1C(ii). It can be seen that hypoxia significantly 
increases GBM spheroid area in both primary and NCH82 cells which has been previously  reported27. This effect 
appears to be stronger for primary cells compared to NCH82 cells.
Vascularized tumoroid model. The vascularized tumoroid model was created by applying vasculariza-
tion techniques to tumor spheroids which were presented in the previous section. This model comprises of 
1000-cell spheroids, consisting of HUVEC and GBM cells at a ratio of 3:1, in a 7.5 mg/mL fibrin gel containing 
106 HDF cells/mL. Both primary and NCH82 GBM cells were used. The primary GBM cells were cultured in 
serum-free medium that preserves the subpopulation of glioblastoma stem-like cells as demonstrated in previ-
ous  work28 using the same cells, whereas the NCH82 GBM cell line was not, resulting in differentiated cells. 
Culturing GBM cells under serum-free conditions with hEGF and hbFGF has been  reported29,30 to tentatively 
preserve the characteristics of the primary brain tumors.
Figure 1B(iii) shows fluorescence images of the GBM : HUVEC spheroids embedded in a 7.5 mg/mL fibrin 
gel containing HDF single cells, at day 3 under hypoxic and normoxic conditions. This tri-culture method was 
found to trigger robust HUVEC angiogenesis creating lumenised capillaries that sprout radially outwards into 
the surrounding fibrin gel. As in the case of HUVEC-only spheroids, angiogenic sprouting is higher at 20%  O2 
compared to 1%  O2. Moreover, the GBM cells behave differently depending on whether they are primary or not. 
NCH82 GBM cells invade into the gel without interacting strongly with the endothelial cells (this is more evident 
at longer timepoints as shown in Figure S3). On the other hand, primary GBM cells integrate more into the vas-
culature behaving similarly to the HUVEC. This phenomenon will be explored further in the following sections.
GBM promotes angiogenesis. In order to investigate the effect of glioblastoma cells on the sprouting 
of endothelial cells, the full tumoroid model (GBM : HUVEC spheroid surrounded by HDF single cells) or 
the exact model but without the GBM cells (HUVEC spheroid with HDF) were compared. Figure 2A depicts 
the angiogenic sprouting of HUVEC spheroids under various co-culture conditions at 1% and 20%  O2. For 
each condition, the explant area, the average vessel length and the junction density are presented in Fig. 2B. 
The results show that in the presence of primary glioblastoma cells, endothelial cells produce vasculature of 
higher explant area but lower interconnectivity. In addition, an increase in the vessel length was observed under 
hypoxic conditions only (Fig. 2B). From the above, we hypothesize an invasive mode of angiogenesis for primary 
GBM cells. This suggests that the cells are producing tumor specific growth factors. The NCH82 GBM cell line 
interacts differently with the endothelial cells inducing sprouting within a smaller explant area while the average 
vessel length remains unaffected. As with the primary GBM, capillaries of lower interconnectivity are produced 
(Fig. 2B).
These results suggest a difference in angiogenic capabilities between primary and NCH82 GBM cells. Patient-
derived primary GBM cells have been cultured under conditions that retain their stem-like  potential28,31 whereas 
in the serum-grown NCH82 cell line the cells are differentiated. This is consistent with in vivo observations as 
tumors that have a high stem cell number are highly  angiogenic15,16. Furthermore, the lower vascular intercon-
nectivity observed in the presence of GBM cells is an important biomimetic feature as it is consistent with the 
high amount of dead ends present in the GBM vasculature compared to normal  vasculature32,33.
GBM as supporting cells. In a related experiment we tested the hypothesis that primary GBM cells can act 
as a supporting cell type for vessel formation, role taken up by the fibroblasts in the previous experiment. For this 
experiment, a 1000-cell HUVEC spheroid was cultured in a 7.5 mg/mL fibrin gel containing 106 cells/mL pri-
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mary or NCH82 GBM single cells. The angiogenic sprouting of HUVEC under 1% and 20%  O2, with or without 
additional growth factors, is illustrated in Fig. 3A for day 3. The number of HUVEC sprouts is shown in Fig. 3B.
When primary GBM is used as a supporting cell, endothelial sprouting is more pronounced in hypoxia com-
pared to normoxia (Fig. 3B). The opposite result is observed for HDF supporting cells (Fig. 2A), demonstrating 
the supporting role primary, serum-free cultured GBM cells have especially under hypoxia even without direct 
intracellular contact. GBM cells are known to secrete pro-angiogenic factors under hypoxia, such as VEGF and 
 bFGF34,35.
Furthermore, the addition of exogenous growth factors enhances this effect for cells cultured at normoxia 
but not at hypoxia suggesting that under hypoxia the GBM cells are already producing a significant amount of 
growth factors (Fig. 3B). In the absence of GBM cells and growth factors, HUVEC undergo a migratory response 
(Figure S1) which suggests that GBM cells are indeed producing pro-angiogenic factors and these factors recruit 
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Figure 2.  Angiogenic sprouting of HUVEC under various culture conditions at day 3 after seeding cultured at 
1% and 20%  O2. (A) Red fluorescence channel images showing sprouting of HUVEC spheroid with HDF, and 
primary or NCH82 GBM : HUVEC spheroid with HDF. HUVEC are shown in red. HDF and GBM cells are 
not visible. The spheroids and single HDF cells are embedded in a 7.5 mg/mL fibrin gel. The scale bars represent 
200 µ m. (B) Graphical representations of the explant area, average vessel length and junction density. Data are 
presented as the mean ± standard deviation; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. Subscript S denotes cells 
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Figure 3.  Angiogenic sprouting of HUVEC spheroids with GBM as the supporting cell at 1% and 20%  O2, 
with or without additional growth factors. (A) Red fluorescence channel images showing HUVEC spheroids 
with supporting primary or NCH82 GBM cells. Images were taken at day 5 after seeding. HUVEC are shown in 
red. GBM single cells are not visible. The spheroids and single GBM cells are embedded in a 7.5 mg/mL fibrin 
gel. The scale bars represent 100 µ m. (B) Graphical representation of the number of HUVEC sprouts. Data are 
presented as the mean ± standard deviation; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. Subscript S denotes cells 
seeded in the same spheroid.
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endothelial cells are found to mostly invade the gel rather than sprout, particularly under normoxia, showing 
that these cells are not so capable of inducing HUVEC vascularization (Fig. 3A).
GBM angiogenic behavior. Time-lapse images of the GBM vascularized tumoroid model depict the evo-
lution of GBM : HUVEC spheroids with HDF single cells at 1%  O2 over 32 h starting at day 1 after seeding. In 
a feature unique to primary GBM vascularized tumoroids, tumor cells grow together with the endothelial cells 
forming sprouting networks. Moreover, as time-lapse imaging shows, some of the formed sprouts are composed 
of primary GBM cells (Fig. 4A). However, in NCH82 vascularised tumoroids, GBM cells break away from the 
primary mass and invade separately into the surrounding matrix (Fig. 4B).
The co-localization between the tumor and the endothelial cells is quantified using the Pearson’s correlation 
coefficient (Fig. 4C). The coefficient is steadily high ∼ 0.75 for primary GBM cells but it decreases from ∼ 0.6 to 
∼ 0.2 for NCH82 GBM cells over 32 h.
CD31 immunohistochemical staining of primary GBM : HUVEC vascularised tumoroids (Fig. 4D) showed 
angionenic sprouting, with cells other than HUVEC expressing CD31, suggesting that the primary GBM cells 
may have transdifferentiated into endothelial cells (Fig. 4D, arrow in the magnified views of the selected area 
(yellow box)). This effect was found to be more prominent under hypoxia which is consistent with what has 
been observed in vivo36,37.
Conclusion
A human, disease-relevant, in vitro vascularized tumoroid model has been developed to investigate microenvi-
ronment cues of glioblastoma (GBM) angiogenesis. The model comprises of GBM and endothelial cell (HUVEC) 
spheroids in a fibrin gel containing human dermal fibroblasts. It is easily scaled up, tractable, cost-effective, 
patient-specific, can employ naturally-derived and synthetic matrices, and is amenable to imaging and detailed 
analysis such as spheroid growth tracking. Although the model lacks perfusable vasculature and has no pre-
existing capillary bed or blood brain barrier, it is complex enough to recapitulate features of GBM angiogenesis, 
which have previously been observed in vivo. Patient-derived primary GBM cells were found to support angio-
genic sprouting when cultured under conditions that preserve their stem-like potential, in contrast to a GBM 
cell line containing differentiated cells. Angiogenic sprouting was observed even in the absence of supportive 
fibroblasts. In the presence of exogenous growth factors, sprouting was enhanced under normoxia but not at 
hypoxia suggesting that hypoxic GBM cells are already producing a significant amount of growth factors. Pri-
mary GBM cells co-cultured with HUVEC in spheroids, produced vasculature of higher explant area and lower 
connectivity in comparison to HUVEC-only spheroids. Under hypoxia, primary GBM cells co-localize with 
HUVEC to form sprouting vascular networks. These findings demonstrate that our 3D tumoroid in vitro model 
exhibits biomimetic attributes. It therefore holds potential as a simple reductionist model for the development 
of anti-angiogenic treatments to GBM especially in view of the need to assess the preliminary effectiveness of 
new treatments before moving to more complex and lengthy efficacy in vivo models.
Methods
Cell culture. Primary GBM cells from fresh surgical samples (Addenbrooke’s Hospital, UK) were derived 
using the Cambridge  Protocol28. Tissue collection protocols complied with the UK Human Tissue Act 2004 (HTA 
license ref. 12315) and have been approved by the local regional ethics committee (LREC ref. 04/Q0108/60). 
Cells were cultured in serum-free medium (SFM) based on phenol red-free Neurobasal A medium (Invitrogen, 
UK) supplemented with 2 mM L-glutamine and 1% Antibiotic - Antimycotic (Life Tech, UK) with 20 ng/mL 
human epidermal growth factor (hEGF, Sigma-Aldrich, UK), 20 ng/mL human basic fibroblast growth factor 
(hbFGF, R & D systems, UK), 2% (v/v) B27 (Invitrogen, UK) and 1%  N2 (Invitrogen, UK). They were propagated 
as monolayers on extracellular matrix-coated flasks (ECM 1:50 dilution, Sigma-Aldrich, UK).
GBM cell line NCH82, a gift from Prof Conceição Pedroso de Lima (University of Coimbra, Portugal), was 
transduced with GFP through lentiviral infection. The NCH82 cell line was cultured in serum-containing, high 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM - high glucose, Life Tech, UK), containing 10% fetal bovine 
serum (FBS, Life Tech, UK) and 1% antibiotic antimycotic solution (Sigma-Aldrich, UK). Primary and NCH82 
GBM cells were passaged at 80% confluency with accutase (Sigma-Aldrich, UK).
Red fluorescent protein expressing HUVEC (2B Scientific,UK) were cultured in Endothelial Growth Medium 
2 (EGM2, Promocell, Germany) and 1% antibiotic antimycotic solution. HDF (Public Health England) were 
cultured in high glucose DMEM containing 10% FBS (Life Technologies, UK) and 1% antibiotic antimycotic 
solution. HUVEC and HDF were passaged at 80% confluency with TrypLE Express (Life Technologies, UK). All 
cells were incubated at 37 °C in 5%  CO2 and 95% relative humidity.
Multi-cellular spheroid formation. Co-culture spheroids were prepared using the hanging drop method. 
A stock solution of methylcellulose was prepared by dissolving 1.2 g methycellulose powder (Sigma-Aldrich, UK) 
in 100 mL of DMEM. GBM and/or HUVEC cells were detached and suspended in 1:1 EGM to SFM medium 
containing 20% methycellulose (v/v). 20 µ L cell suspension drops each containing 1000 cells were pipetted onto 
a non-adherent petri dish (Greiner, UK). Co-culture spheroids were composed of HUVEC to GBM at a 3:1 ratio. 
HUVEC-only and GBM-only spheroids were also generated. The dish was turned upside down and incubated at 
37 °C. The spheroids were harvested after 16 h.
Gel construct preparation. For each fibrin construct, approximately 3 spheroids were embedded in 25 µ L 
of fibrin gel. Fibrin gels contained HDF or GBM at 106 cells/mL or no cells. To prepare the fibrin gel, fibrinogen 
was dissolved in 1:1 EGM2 to SFM medium, with or without additional pro-angiogenic growth factors (200 ng/
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mL VEGF and bFGF), to a final concentration of 7.5 mg/mL and was mixed with 1 µ L of 50 U/mL thrombin. 
The solution was pipetted into a 48-well plate, turned upside down, left at room temperature undisturbed for 10 
min and then moved to a 37 °C incubator for 20 min to completely polymerise. 1:1 EGM to SFM medium was 
t = 0 h t = 4 h t = 8 h t = 12 h
t = 0 h t= 8 h t = 24 ht = 16 h t = 32 h
B
A (Primary GBM : HUVEC)S, HDF at 1% O2 
(NCH82 GBM : HUVEC)S, HDF at 1% O2 
t = 16 h
t = 20 h t = 24 h t = 28 h t
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Figure 4.  Time-lapse imaging showing evolution of GBM: HUVEC spheroid with HDF as the supporting cell 
at 1%  O2 over a period of 32 h. (A) Primary GBM (green) : HUVEC (red) spheroid. (B) NCH82 GBM (green) 
: HUVEC (red) spheroid. t = 0 h is taken at day 1 after seeding. HDF cells are non-fluorescent. The spheroids 
and single HDF cells are embedded in a 7.5 mg/mL fibrin gel. (C) Plot showing Pearson’s correlation coefficient 
as a function of culture time. Similar results were obtained in three independent experiments. (D) CD31 
immunohistochemical staining (green) of primary GBM : HUVEC spheroid at day 3 after seeding. Right images 
are magnified views of the selected area (yellow box). The scale bars represent 100 µ m. Subscript S denotes cells 
seeded in the same spheroid.
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then added. Fibrin constructs were maintained at either 20%  O2 (normoxia) or 1%  O2 (hypoxia). Medium was 
changed every 2 days.
Fluorescent labelling. Primary GBM cells were labelled using Qtracker 525 (ThermoFisher Scientific, 
UK). Cells were subcultured at a density of 2 × 104 cells per well of a 48-well plate and incubated overnight. Then 
200 µ L of 15 nM Qtracker diluted in SFM was added per well. Cells were then incubated for 6 h before washing 
them twice with SFM.
Tumoroids were immunofluorescently stained with CD31 antibody. Gel constructs were fixed using 4% para-
formaldehyde (PFA, Sigma-Aldrich, UK) for 1 hour followed by washes with phosphate-buffered saline (PBS, 
Sigma-Aldrich, UK). The constructs were subsequently permeabilised with 0.25% Triton X-100 (Sigma-Aldrich, 
UK) and blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich, UK). Cells were incubated overnight 
with CD31 antibody (Abcam, UK) diluted at 1:100 followed by 2 h of incubation with 1:500 AlexaFluor 568 goat 
anti-mouse IgG (abcam, UK) diluted at 1:500. Washes with PBS followed both incubation periods.
Visualization and quantification of sprouting angiogenesis. Images of sprouting tumoroids were 
taken using epi-fluorescence microscopy (Zeiss Axio Observer Z1 inverted microscope with an ORCA-Flash4.0 
camera). The microscope was equipped with an incubator regulating  CO2 (5%),  O2 (20% or 1%), temperature 
(37 °C) and humidity (95%) (Okolab, Italy). Time-lapse images were acquired every 20 min. The images were the 
result of the deconvolution of an image z-stack using ZEN 3.0  software38.
The area of the vessel networks that extended beyond the surface of the initial spheroid boundary was selected 
using ImageJ. This area was then analysed using  AngioTool39. The software provided automatic measurements 
of: (i) the total vessel area, (ii) the total vessel length, (iii) the explant area (area of convex hull containing all the 
vessels), (iv) the average vessel length and (v) the junction density (total number of vessel junctions normalised 
by the area). A vessel was defined as the segment between two junction points or a junction point and an end 
point. The total spheroid area (area of spheroid including any sprouting) was quantified in ImageJ.
GBM co-localization along blood vessels was quantified by the Pearson’s correlation coefficient in Coloc  240 
(ImageJ  plugin41).
Statistical analysis. Data comparisons between two sets of data were performed in GraphPad Prism 8.4.3 
 software42. Data are displayed as mean ± standard deviation. Three spheroids were analysed out of each one of 
three independent experiments. The explant area of each spheroid ranged between  0.1 and  1.3 mm2 . Two sets 
of data were compared using the Students t-test. The threshold for statistical significance was set at a value of *p 
< 0.05. **p < 0.01; ***p < 0.001.
Accession codes. The datasets generated and analysed during the current study are available to download 
from Mendeley Data, V1, https:// doi. org/ 10. 17632/ kc64v 677tb.1.
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